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Introduction
Mucopolysacharidoses (MPS) are lysosomal storage dis-
orders characterized by a deficiency/absence of a enzyme
involved in the degradation of glycosaminoglycans
(GAG) The diagnosis is frequently delayed as the quanti-
fication of GAG in urine is not routinely performed. We
developed a qualitative method to detect high GAG levels
in urine to provide an early diagnosis even in low suspi-
cion cases of MPS in children.
Methods
Glycosaminoglicans react with 1,9-dimethylmethylene
blue (DMB) in acidic medium yielding a pink colour.
Optimum DMB concentration discriminates between
pathological and normal excretion.
Test: 50 μl of urine with 2 ml of DMB solution. The final
colour is compared against a scale.
The urine of 51 diagnosed MPS patients and 169 healthy
child samples were essayed.
Results
A pink colour is developed when the sample contains
more than 200 mg/L of GAG. The selected concentration
gave a positive response in all untreated patients. Negative
or dubious in Morquio and Sly diseases whose GAG excre-
tion is low and in some patients under enzymatic treat-
ment. Hurler, Hunter and Maroteau-Lamy were
successfully detected, regardless of the creatinine clear-
ance. Only two controls with high creatinine levels were
dubious
Conclusion and proposal
GAG testing has proved to be useful for a rapid diagnosis
of MPS with high GAG excretion.
This test provides an aid to rheumatologist in detecting
patients with alerting musculoskeletal symptoms like
joint stiffness, flexion contractures without evident
inflammation, carpel tunnel syndrome or multiple trigger
finger in cases of MPS-I.
We suggest using GAG testing in the screening of such
dubious cases.
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